Carlumab

Carlumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	MCP-1
Clinical data
ATC code	none
Identifiers
CAS Number	915404-94-3^N
ChemSpider	none
Chemical and physical data
Formula	C₆₄₄₂H₉₉₆₆N₁₇₀₆O₂₀₁₈S₄₀
Molar mass	144.88 kg/mol
^NY (what is this?) (verify)

Carlumab is a human monoclonal antibody designed for oncology and immune indications.^[1]^[2]

Carlumab was developed by Johnson & Johnson.

References

↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab" (PDF). American Medical Association.
↑ World Health Organization (2010). "Proposed International Nonproprietary Names: List 104" (PDF). WHO Drug Information. 24 (4). Geneva: World Health Organization. p. 361. ISSN 1010-9609. Retrieved 17 August 2015.

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	Immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Belimumab Brodalumab Carlumab Dupilumab Durvalumab Eldelumab Fresolimumab Golimumab Lanadelumab Lenzilumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oxelumab§ Placulumab Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Nivolumab Pembrolizumab Tremelimumab Urelumab Other: Bertilimumab Zanolimumab

Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab

Humanized ("-lizu-")	Immunosuppressive: Aselizumab Apolizumab Benralizumab^† Cedelizumab Certolizumab pegol Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Inebilizumab Itolizumab Lampalizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Quilizumab Samalizumab Siplizumab Talizumab Teplizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Lebrikizumab Olokizumab Perakizumab Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Chemokine receptor modulators

CCR1	Agonists: CCL4 (MIP-1β) CCL5 (RANTES) CCL6 CCL9 (CCL10) CCL14 CCL15 CCL16 CCL23

CCR2	Agonists: CCL2 CCL8 CCL12 CCL16 NAMs: Cenicriviroc (TAK-652, TBR-652)

CCR3	Agonists: CCL5 (RANTES) CCL7 CCL11 CCL13 CCL15 CCL18 CCL24 CCL26 CCL28

CCR4	Agonists: CCL3 (MIP-1α) CCL5 (RANTES) CCL17 CCL22 Antibodies: Mogamulizumab (against CCR4)

CCR5	Agonists: CCL3 (MIP-1α) CCL4 (MIP-1β) CCL5 (RANTES) CCL8 CCL11 CCL13 CCL14 CCL16 NAMs: Aplaviroc Cenicriviroc (TAK-652, TBR-652) INCB009471 Maraviroc Vicriviroc Antibodies: PRO-140

CCR6	Agonists: CCL20

CCR7	Agonists: CCL19 CCL21

CCR8	Agonists: CCL1 CCL16

CCR9	Agonists: CCL25

CCR10	Agonists: CCL27 CCL28

CCR11	Agonists: CCL19 CCL21 CCL25

Ungrouped	Antibodies: Bertilimumab (against CCL11) Carlumab (against CCL2)

CXC

CXCR1 (IL-8Rα)	Agonists: CXCL6 Emoctakin Interleukin-8 (CXCL8, GCP-1) Antagonists: Navarixin NAMs: Ladarixin Reparixin (repertaxin)

CXCR2 (IL-8Rβ)	Agonists: CXCL1 (MGSA) CXCL2 CXCL3 CXCL5 CXCL6 CXCL7 Emoctakin Garnocestim Interleukin-8 (CXCL8, GCP-1) Antagonists: Danirixin Elubrixin Navarixin NAMs: Ladarixin Reparixin (repertaxin)

CXCR3	Agonists: CXCL4 (PF4) CXCL9 (MIG) CXCL10 (IP-10) CXCL11 (I-TAC) Iroplact Antibodies: Eldelumab (against CXCL10)

CXCR4	Agonists: MIF SDF-1 (CXCL12) Ubiquitin Antagonists: Plerixafor (AMD3100) Antibodies: Ulocuplumab (against CXCR4)

CXCR5	Agonists: CXCL13

CXCR6	Agonists: CXCL16

CXCR7	Agonists: CXCL11 (I-TAC) SDF-1 (CXCL12) PAMs: Plerixafor (AMD3100)

C (XC)

XCR1	Agonists: Lymphotactin-α (XCL1) Lymphotactin-β (XCL2) Antibodies: Pateclizumab

CX3C

CX3CR1	Agonists: Fractalkine (CX3CL1)

Others

CCBP2	Agonists: CC (β) chemokines

CMKLR1	Agonists: Chemerin Resolvin E1

See also: Cytokine receptor modulators
Peptide receptor modulators

This article is issued from Wikipedia - version of the 9/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.